Clinical Trial â Side Effects of Combination Treatment for Melanoma â Melanoma
Melanoma is a cancer of melanocytes–melanin pigment producing cells, and the cancer originates in the skin, uvea, acral tissues and mucosal tissues. Melanoma incidence and mortality are increasing in the U.S. with over 80,000 cases/year and 9,000 deaths/year. Advanced melanoma occurs either after treatment for localized melanoma or de novo and is associated with chemo-resistance and a median survival of 9 months.
This study is being done to find out if the combination of dabrafenib, trametinib and digoxin will lessen the side effects that you may experience and to measure your response and duration of response to the combination of drugs.
| Study Type  : | Interventional  (Clinical Trial) |
| Estimated Enrollment  : | 20 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1B Clinical Trial of Dabrafenib, Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma |
| Study Start Date  : | October 2016 |
| Estimated Primary Completion Date  : | July 2019 |
| Estimated Study Completion Date  : | July 2020 |
Contacts
| Contact: Joyce Bolluyt, Rn | 214-648-7097 | Joyce.Bolluyt@UTSouthwestern.edu |
Locations
| United States, Texas | |
| University of Texas Southwestern Medical Center | Recruiting |
| Dallas, Texas, United States, 75063 | |
| Contact: Joyce Bolluyt, RN Â Â 214-648-7097 Â Â Â joyce.bolluyt@utsouthwestern.edu | |
| Principal Investigator: Arthur Frankel, MD | |
| ClinicalTrials.gov Identifier: | NCT02915666 |
* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.